Bio-Path’s (BPTH) Buy Rating Reiterated at Roth Mkm

Roth Mkm reissued their buy rating on shares of Bio-Path (NASDAQ:BPTHFree Report) in a report issued on Monday morning, Benzinga reports. They currently have a $20.00 target price on the stock.

Separately, started coverage on Bio-Path in a research report on Thursday, May 2nd. They set a sell rating on the stock.

Check Out Our Latest Stock Report on BPTH

Bio-Path Price Performance

Shares of BPTH opened at $1.83 on Monday. Bio-Path has a 52-week low of $1.59 and a 52-week high of $30.90. The business’s 50 day moving average price is $2.25 and its two-hundred day moving average price is $5.13.

Bio-Path (NASDAQ:BPTHGet Free Report) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($4.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.54) by ($0.34). As a group, research analysts forecast that Bio-Path will post -5.53 earnings per share for the current fiscal year.

About Bio-Path

(Get Free Report)

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

Further Reading

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with's FREE daily email newsletter.